Arcus Biosciences and AstraZeneca have partnered to evaluate a combination therapy as a potential treatment for advanced non-small cell lung cancer (NSCLC).
If you are not happy with the results below please do another search
50 search results for:
Sanofi is testing the company’s non-alpha IL-2 candidate THOR-707 with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors.
Novartis acquired Cambridge, Massachusetts-based Vedere Bio in a deal totaling up to $280 million.
Fishawack Health launched a pro bono campaign on World Psoriasis Day to raise awareness that psoriasis is not a contagious or unhygienic condition and to help lessen the stigma, discrimination, and exclusion of the 125 million people living with the skin condition globally.
Swiss drugmaker Roche plans to boost rapid Covid-19 antigen test production to hundreds of millions monthly – including possible saliva tests – Chief Executive Severin Schwan said, acknowledging the fierceness of the pandemic’s second wave took him by surprise.
W2O announced two new products available through Symplur, the company’s social media analytics platform dedicated exclusively to the healthcare industry.
Moderna Inc. is on track to report early data from a late-stage trial of the company’s Covid-19 vaccine candidate in November, offering the clearest timeline yet on when the world will know whether the vaccine is effective.
Cerevel Therapeutics began trading on the Nasdaq.
Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.
Shionogi & Co. is planning clinical trials by year-end 2020 for what may be one of Japan’s first domestically produced Covid-19 vaccines to reach the market, as the globe races to secure enough doses to battle the pandemic.